What question did this study set out to answer?

Determine the prevalence and prognostic significance of IDH1 and IDH2 mutations in newly diagnosed acute myeloid leukemia patients within the GIMEMA AML1516 protocol.

June 18, 2022CancersOpen Access

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

View Full Paper

Ask AI

Bookmark

Authors

MMMonica MessinaFondazione Gimema Onlus APAlfonso PiciocchiUniversity of Rome Tor Vergata TOTiziana OttoneUniversity of Rome Tor Vergata

Discussion

Member takes

Implication

Observational study reveals IDH1/2 mutation prevalence and survival outcomes in acute myeloid leukemia, highlighting the need for upfront molecular profiling to guide targeted therapies.

Key Points

Determine the prevalence and prognostic significance of IDH1 and IDH2 mutations in newly diagnosed acute myeloid leukemia patients within the GIMEMA AML1516 protocol.
Analyzed 284 consecutive newly diagnosed AML patients (median age 65 years, range 19–86; 139 females, 145 males) in Italy.
Evaluated IDH1 and IDH2 mutation status alongside cytogenetics, NPM1 mutations, clinical parameters, and survival outcomes.
IDH1 mutations occurred in 14% (38/284) and IDH2 mutations in 18% (51/284) of patients, significantly associating with WHO performance status >2 (p < 0.001) and non-complex karyotype (p = 0.021).
IDH1 mutations correlated significantly with NPM1 co-mutations (p = 0.007) and elevated platelet counts (p = 0.036); IDH1/2 mutations appeared in 25% (6/24) of relapsed cases.
Among IDH1/2-mutated patients, complete remission reached 60.5%, 2-year overall survival was 44.5%, and 2-year event-free survival was 36.1% (comparable to wild-type), with high white blood cell count serving as an independent adverse prognostic factor.

Cite This Study

Messina et al. (2022) studied this question.

synapsesocial.com/papers/69df24013b0ba53fb37a188e https://doi.org/10.3390/cancers14123012

View Full Paper

Ask AI

Bookmark

Implication

Observational study reveals IDH1/2 mutation prevalence and survival outcomes in acute myeloid leukemia, highlighting the need for upfront molecular profiling to guide targeted therapies.

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Discussion

Member takes

Implication

Key Points

Cite This Study

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider